Jakarta, March 12, 2026 – Global economic turmoil continues to put pressure on the Rupiah's exchange rate in 2026, triggering serious concerns across various sectors. One of the most vulnerable sectors is health, where Health Minister Budi Gunadi Sadikin recently issued a warning about a potential significant increase in drug prices.
Potential Drug Price Hikes Up To 20%
In his statement to the media, Health Minister Budi Gunadi Sadikin revealed that the weakening Rupiah could drive drug prices in the domestic market up by 10% to 20%. “We are closely monitoring the Rupiah’s exchange rate movements, which continue to face pressure,” stated Minister Sadikin. “Most pharmaceutical raw materials, and even certain finished drug products, are still heavily reliant on imports. When the Rupiah weakens, import costs automatically surge, and this will ultimately be reflected in retail prices at pharmacies.”
Nevertheless, the Minister emphasized that the government would strive to ensure that any price adjustments remain within reasonable limits and do not unduly burden the public. “Our priority is to maintain the accessibility of essential medicines, especially for vulnerable groups. We will collaborate with manufacturers and distributors to find mitigation solutions,” he added.
Economic Impact and Industry Response
The increase in drug prices will undoubtedly have broad economic implications, particularly for households and the national health insurance system. Dr. Mira Sumanto, a health economist from the University of Indonesia, explained, “The weakening of the Rupiah in 2026 is not just about imports. It also reflects broader inflation challenges and global market uncertainties. Increased operational and logistics costs for the pharmaceutical industry are inevitable, and this demands a comprehensive policy response from the government.”
Meanwhile, representatives from the Indonesian Pharmaceutical Entrepreneurs Association (GPFI) stated that the industry has tried to curb price increases for as long as possible, but the pressure of high input costs has become unavoidable. “We understand the concerns of the public and the government. However, the sustainability of production and drug availability must also be considered. We hope for incentives or subsidies from the government to alleviate this burden,” said a GPFI spokesperson.
Mitigation Steps and Future Outlook
The government is reportedly preparing several mitigation measures, including the potential acceleration of raw material import substitution with local products, price negotiations with manufacturers, and strengthening the National Health Insurance (JKN) program to cover higher drug costs. “The government, through the Ministry of Health and BPJS Kesehatan, will continue to coordinate to ensure that the public, especially JKN participants, continues to receive the necessary health services and medicines without significant hindrance,” affirmed Minister Sadikin.
The public is urged to remain calm and consult with medical professionals or pharmacists about potentially more affordable generic drug alternatives. This situation underscores the importance of collaboration among the government, the pharmaceutical industry, and the community to jointly address these economic challenges in the health sector.
